LOS ANGELES, May 4, 2023 /PRNewswire/ — ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the pricing of its upsized initial public offering of 30,000,000 shares of…